Form 4: Corvus Pharmaceuticals Director Ian T. Clark Reports Stock Option Grant

Director Ian T. Clark reports acquisition of stock options in Corvus Pharmaceuticals.

Summary

• On June 13, 2024, Ian T. Clark, a director of Corvus Pharmaceuticals, Inc., was granted stock options to purchase 15,000 shares of common stock.
• The exercise price of the options is $2.12 per share.
• The options vest on the earlier of June 13, 2025, or the date of the 2025 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.
• The options expire on June 13, 2034.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing regarding stock option grants, which is generally neutral. It indicates continued alignment of a director with the company's interests.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders, incentivizing him to work towards increasing the company's value.

Future Outlook

The vesting of the options is contingent upon continued service as a director, suggesting an expectation of ongoing involvement with the company.

Industry Context

Stock option grants are a common form of executive compensation in the pharmaceutical industry, used to attract and retain talent and align their interests with those of shareholders.

Stakeholder Impact

• The stock option grant could have a minor positive impact on shareholder sentiment as it aligns the director's interests with those of the shareholders.

Key Dates